The use of low–molecular weight heparin bridge therapy during warfarin interruption for elective surgery/procedures increases bleeding. Other predictors of bleeding in this setting are not well described.Methods
BRIDGE was a randomized, double-blind, placebo-controlled trial of bridge therapy with dalteparin 100 IU/kg twice daily in patients with atrial fibrillation requiring warfarin interruption. Bleeding outcomes were documented from the time of warfarin interruption until up to 37 days postprocedure. Multiple logistic regression and time-dependent hazard models were used to identify major bleeding predictors.Results
We analyzed 1,813 patients of whom 895 received bridging and 918 received placebo. Median patient age was 72.6 years, and 73.3% were male. Forty-one major bleeding events occurred at a median time of 7.0 days (interquartile range, 4.0–18.0 days) postprocedure. Bridge therapy was a baseline predictor of major bleeding (odds ratio [OR] = 2.4, 95% CI: 1.2–4.8), as were a history of renal disease (OR = 2.9, 95% CI: 1.4–6.0), and high–bleeding risk procedures (vs low–bleeding risk procedures) (OR = 2.9, 95% CI: 1.4–5.9). Perioperative aspirin use (OR = 3.6, 95% CI: 1.1–11.9) and postprocedure international normalized ratio >3.0 (OR = 2.1, 95% CI: 1.5–3.1) were time-dependent predictors of major bleeding. Major bleeding was most common in the first 10 days compared with 11–37 days postprocedure (OR = 3.5, 95% CI: 1.8–6.9).Conclusions
In addition to bridge therapy, perioperative aspirin use, postprocedure international normalized ratio >3.0, a history of renal failure, and having a high–bleeding risk procedure increase the risk of major bleeding around the time of an elective surgery/procedure requiring warfarin interruption.